Investors

Latest Report

2016 - Q3 Quarterly Report

Prometic reports third quarter 2016 highlights and financial results
- Acquisition of Telesta Therapeutics adds $37.4 million in cash and short-term investments to $39.0 million balance reported at end of Q3
- Investment in commercial & manufacturing infrastructure ahead of plasminogen commercial launch included in R&D expense
- Plasminogen pivotal clinical trial results performed at 100% response rate meeting primary and secondary end points in plasminogen deficient patients
- Primary and secondary endpoints met in clinical trials in metabolic syndrome patients
- 2016 YTD revenues of $12.3 million vs. $10.5 million for same 2015 period

Download

Annual Report

Annual Report 2015

Building a company to bring safer therapeutic products.

Download Link View all reports

Presentation

Prometic Corporate Presentation January 2017

Experts in bioseparation, plasma derived and small molecule drugs.

Download Link View all presentations
X